Chromadex Corp
ChromaDex Corporation operates as a bioscience company engages in developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; nicotinamide adenine dinucleotide (NAD+) t… Read more
Market Cap & Net Worth: Chromadex Corp (CDXC)
Chromadex Corp (NASDAQ:CDXC) has a market capitalization of $611.90 Million ($611.90 Million) as of March 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #11378 globally and #5091 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Chromadex Corp's stock price $7.87 by its total outstanding shares 77750400 (77.75 Million).
Chromadex Corp Market Cap History: 2015 to 2025
Chromadex Corp's market capitalization history from 2015 to 2025. Data shows growth from $284.57 Million to $611.90 Million (7.78% CAGR).
Index Memberships
Chromadex Corp is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Composite
IXIC
|
$33.39 Trillion | 0.00% | #1141 of 3165 |
Weight: Chromadex Corp's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Chromadex Corp Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Chromadex Corp's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
6.70x
Chromadex Corp's market cap is 6.70 times its annual revenue
1728.56x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
48.24x
Chromadex Corp's market cap is 48.24 times its annual earnings
0.11x
Higher than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $284.57 Million | $22.01 Million | -$2.77 Million | 12.93x | N/A |
| 2016 | $257.35 Million | $26.81 Million | -$2.93 Million | 9.60x | N/A |
| 2017 | $457.17 Million | $21.20 Million | -$11.38 Million | 21.56x | N/A |
| 2018 | $266.68 Million | $31.56 Million | -$33.32 Million | 8.45x | N/A |
| 2019 | $335.10 Million | $46.29 Million | -$31.47 Million | 7.24x | N/A |
| 2020 | $373.20 Million | $59.26 Million | -$18.48 Million | 6.30x | N/A |
| 2021 | $290.79 Million | $67.45 Million | -$25.56 Million | 4.31x | N/A |
| 2022 | $130.62 Million | $72.05 Million | -$14.45 Million | 1.81x | N/A |
| 2023 | $111.18 Million | $83.57 Million | -$4.94 Million | 1.33x | N/A |
| 2024 | $412.47 Million | $61.59 Million | $8.55 Million | 6.70x | 48.24x |
Competitor Companies of CDXC by Market Capitalization
Companies near Chromadex Corp in the global market cap rankings as of March 18, 2026.
Key companies related to Chromadex Corp by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Chromadex Corp Historical Marketcap From 2015 to 2025
Between 2015 and today, Chromadex Corp's market cap moved from $284.57 Million to $ 611.90 Million, with a yearly change of 7.78%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $611.90 Million | +48.35% |
| 2024 | $412.47 Million | +270.98% |
| 2023 | $111.18 Million | -14.88% |
| 2022 | $130.62 Million | -55.08% |
| 2021 | $290.79 Million | -22.08% |
| 2020 | $373.20 Million | +11.37% |
| 2019 | $335.10 Million | +25.66% |
| 2018 | $266.68 Million | -41.67% |
| 2017 | $457.17 Million | +77.64% |
| 2016 | $257.35 Million | -9.56% |
| 2015 | $284.57 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 17th, 2026 the market cap of Chromadex Corp was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $611.90 Million USD |
| MoneyControl | $611.90 Million USD |
| MarketWatch | $611.90 Million USD |
| marketcap.company | $611.90 Million USD |
| Reuters | $611.90 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.